Identifying
ongoing hemolysis

Despite normalization across some key measures, hemolysis may persist1

PATIENT PROFILES
Consider the clinical profile of a patient*
with PNH currently on C5 inhibition.
Megan,
35 years old*
Megan,
35 years old*
Charlie,
47 years old*
Charlie,
47 years old*
*Hypothetical patient. The hypothetical
patient profiles are based on the
following sources: Schrezenmeier
Haematologica 2014, Risitano Front
Immunol 2019, Risitano Blood 2009,
Young Semin Hematol 2009,
and McKinley Blood 2017.
*Hypothetical patient. The hypothetical
patient profiles are based on the
following sources: Schrezenmeier
Haematologica 2014, Risitano Front
Immunol 2019, Risitano Blood 2009,
Young Semin Hematol 2009,
and McKinley Blood 2017.
Below normal levels
of Hb

Hemoglobin is the most direct indicator of clinical severity in hemolytic diseases. Hemoglobin levels are pivotal for treatment response evaluation4

Elevated levels of LDH

In hemolytic conditions, LDH is often increased, and may be useful in distinguishing between EVH and IVH (can be slightly increased in EVH and multiple-fold greater than the ULN in IVH)4

Elevated ARC

Reticulocyte count is an indicator of bone marrow function and levels are usually increased in hemolysis4

Elevated levels
of bilirubin

Elevated bilirubin levels can be caused by increased hemoglobin breakdown in the liver and spleen4

patients who struggle with unresolved symptoms may need more from treatment1

ARC=absolute reticulocyte count; EVH=extravascular hemolysis; Hb=hemoglobin; IVH=intravascular hemolysis; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria; QoL=quality of life; RBC=red blood cell; ULN=upper limit of normal.

References: 1. Risitano AM, et al. Front Immunol. 2019;10:1157. 2. Schrezenmeier H, et al. Haematologica. 2014;99(5):922-929. 3. Young N, et al. Semin Hematol. 2009;46(1 suppl 1):S1-S16. 4. Barcellini W, et al. Dis Markers. 2015;2015:1-7. 5. Risitano AM, et al. Blood. 2009;113(17):4094-4100. 6. Ueda Y, et al. Int J Hematol. 2018;107(6):656-665. 7. Hill A, et al. Haematologica. 2010;95(4):567-573. 8. Brodsky RA. Blood. 2014;124(18):2804-2811. 9. Lee JW, et al. Am J Hematol. 2019;94:S1-S2. 10. Lee JW, et al. Am J Hematol. 2019;94(1):E37-E41.